GLP-1 and Heart Health: What the SELECT Trial Really Found

The SELECT trial showed that semaglutide 2.4 mg (the active ingredient in Wegovy) reduced major adverse cardiovascular events by 20% in adults with obesity and established heart disease who did not have diabetes. Published in the New England Journal of Medicine in 2023, SELECT (Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity) is one of the most important obesity trials ever run.

The study enrolled 17,604 adults aged 45 and older with a BMI of 27 or higher and pre-existing cardiovascular disease, then randomly gave them either weekly semaglutide or a placebo and followed them for a mean of about 40 months. The primary endpoint, a combination of cardiovascular death, non-fatal heart attack, and non-fatal stroke, occurred in 6.5% of the semaglutide group versus 8.0% of the placebo group, a 20% relative risk reduction (hazard ratio 0.80; p<0.001). In plain terms, treating people with obesity and heart disease using semaglutide measurably prevented heart attacks, strokes, and cardiovascular deaths. This was the first time a weight-loss medication was proven to protect the heart in people without diabetes, which is why it reshaped how doctors think about treating obesity itself as a cardiovascular risk.

GLP-1 drugs protect the heart through several overlapping mechanisms, not just weight loss. While shedding excess fat clearly helps the cardiovascular system, one of the most striking findings from SELECT was that the heart benefit began to appear early, before participants had lost much weight, which tells researchers that other pathways are at work.

The leading explanations include reduced inflammation, a key driver of the artery-clogging process called atherosclerosis; improved function of the endothelium, the delicate lining of blood vessels; modest reductions in blood pressure; better blood sugar control; and direct effects on the heart and blood vessels where GLP-1 receptors are present. Semaglutide also lowers a blood marker of inflammation called C-reactive protein (CRP). Of course, the weight loss itself matters too, easing the heart's workload, improving cholesterol and blood pressure, and reducing the strain that excess body fat places on the cardiovascular system. The picture that emerges is of a drug class that helps the heart on multiple fronts at once. This is also why the cardiovascular benefit is exciting beyond weight: it suggests GLP-1s treat some of the underlying biology of cardiovascular disease, not just the number on the scale. Researchers are now studying these mechanisms in dedicated trials.

The people who benefit most from the cardiovascular effects of GLP-1s are those who match the SELECT population: adults with obesity or overweight plus established cardiovascular disease, such as a prior heart attack, stroke, or peripheral artery disease. For this group, the evidence that semaglutide prevents repeat cardiovascular events is now strong, and it adds a reason to consider treatment beyond weight alone.

People with type 2 diabetes also gain cardiovascular protection from GLP-1s, shown in earlier trials, and the related medication tirzepatide is being studied in its own outcomes trials. What SELECT did not test is whether GLP-1s prevent first-ever heart events in otherwise healthy people with obesity but no heart disease, so the benefit should not be over-generalized to everyone. It is also important to understand that GLP-1s complement, rather than replace, standard heart care. Statins for cholesterol, blood pressure medication, not smoking, and physical activity remain foundational. If you have both excess weight and heart disease, the SELECT findings are worth discussing with your doctor, because the cardiovascular benefit may tip the balance toward treatment and may affect insurance coverage. As with any medication, the decision depends on your full health picture, other conditions, and tolerance of side effects like nausea.

Yes. On the strength of SELECT, the FDA approved Wegovy in March 2024 to reduce the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease and either obesity or overweight. This was a landmark label expansion because it recognized a weight-loss drug as a cardiovascular medicine.

The practical consequences are significant. A cardiovascular indication gives doctors a stronger, evidence-based reason to prescribe, and it opened the door to broader insurance coverage, including a 2025 decision by Medicare to cover semaglutide specifically for eligible patients with heart disease, separate from the broader weight-loss coverage debates. For patients who previously could not get a GLP-1 covered for weight loss alone, a documented history of cardiovascular disease may now change the equation. This matters because cost and coverage are among the biggest barriers to GLP-1 access. If you have heart disease and obesity, it is worth asking your prescriber whether the cardiovascular indication applies to you and could support coverage. The bigger story is a shift in medicine: obesity is increasingly treated as a serious, treatable contributor to cardiovascular disease rather than a cosmetic concern, and trial evidence like SELECT is what made that shift possible.

GLP-1s have a reassuring cardiovascular safety record, but they are not free of side effects, and a few heart-related points are worth understanding. In SELECT, more participants stopped semaglutide because of side effects than placebo, mainly gastrointestinal issues like nausea, vomiting, and diarrhea, rather than heart problems. The trial did not show an increase in serious cardiac harms; if anything, the cardiovascular signal was protective.

That said, a few practical cautions apply. GLP-1s can slightly raise heart rate, usually by a few beats per minute, which is generally well tolerated but worth monitoring in people with certain arrhythmias. Rapid weight loss and reduced food and fluid intake can occasionally cause dehydration or electrolyte shifts, which matter for heart rhythm, so staying hydrated and keeping up nutrition is important. People with a history of certain conditions, including medullary thyroid cancer or pancreatitis, should not take these drugs, and anyone with heart disease should coordinate GLP-1 treatment with their cardiologist. The bottom line is that for appropriate patients the cardiovascular benefits demonstrated in SELECT outweigh these manageable risks, but GLP-1 therapy still belongs within a complete care plan that monitors your heart, hydration, and overall health rather than being managed in isolation.